Article thumbnail

Analog insulin detemir for patients with type 1 and type 2 diabetes: a review

By Gregory E Peterson
Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3047999
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2009). A comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabetes Care.
  2. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when added to glucose-lowering drugs in insulin-naïve people with Type 2 diabetes.
  3. Association with glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study.
  4. (2004). Benefits of insulin detemir over NPH insulin in children and adolescents with type 1 diabetes: lower and more predictable fasting plasma glucose and lower risk of nocturnal hypoglycemia. Diabetes.
  5. (2005). Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir versus morning plus bedtime NPH insulin. Diabetic Med.
  6. (2004). Effects of QD insulin detemir or neutral protamine hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal- bolus regimen. Clin Ther.
  7. Efficacy and safety of insulin detemir in a large cohort of patients with type 2 diabetes suing a simplified self-adjusted dosing guideline
  8. (2008). Glycemic control in diabetes: a tale of three studies. Diabetes Care.
  9. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes.
  10. (2004). Insulin detemir and insulin aspart: a promising basal-bolus regimen for Type 2 diabetes. Diabetes Res Clin Pract.
  11. (2008). Insulin detemir in type 1 and type 2 diabetes [abstract]. Ehrlich II World Congress,
  12. Insulin detemir is associated with lower risk of hypoglycemia than
  13. (2003). Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type1 diabetes. Diabetes Care.
  14. (2008). Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatr Diabetes.
  15. (2004). Insulin detemir offers improved glycemic control compared with NPH insulin in people with type I diabetes: a randomized clinical trial. Diabetes Care.
  16. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
  17. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The Diabetes Control and Complications Trial/
  18. Intensive Glycemic Control in the ACCORD and ADVANCE Trials.
  19. (2004). Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes.
  20. (2006). Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Curr Med Res Opin.
  21. (2008). Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabet Med.
  22. (2005). Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab.
  23. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes.
  24. Reducing oxidative stress in patients with type 2 diabetes mellitus: A primary care call to action.
  25. Should minimal blood glucose variability become the gold standard of glycemic control?
  26. (2002). Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK. Prospective Diabetes Study (UKPDS 57). Diabetes Care.
  27. Targeting postprandial hyperglycemia.
  28. (1996). The Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications.
  29. (1993). The effect of long-term intensified insulin treatment of microvascular complications of diabetes mellitus.